Blood · 1980 · 69 citations · 13 references
MedicineHematologyOncologyChemotherapyCytogeneticsHematologic OncologyCancer CytogeneticsChemotherapy In Hematologic MalignanciesChemotherapy ResistanceClinical CytogeneticsHematologic MalignanciesHematopoietic NeoplasmsChronic LeukemiasChronic Myeloid Leukemia TherapyCytogenetic RelapseCytogenetics In Hematologic DiseaseLeukemia CytogeneticsLeukemia PathologyMyeloablative ChemotherapyRelapsed Leukemia
After intensive chemotherapy, marrow cells of some patients with Philadelphia chromosome (Ph1) positive chronic myelogenous leukemia (CML) become partially or completely Ph1-negative. However, without a second marker for the neoplastic clone, it could not be determined if these Ph1-negative cells arose from normal progenitors or were still members of an abnormal clone. In the present study, a patient with Ph1-positive CML, also heterozygous for glucose-6-phosphate dehydrogenase (G6PD), was studied before and after intensive chemotherapy. Prior to treatment only G6PD type B was detected in the patient's red cells, platelets, and granulocytes, and all unstimulated marrow metaphases had Ph1. After four cycles of chemotherapy, 76% of marrow cells were Ph1-negative, and approximately 80% of the granulocytes were nonclonal by G6PD analysis. Thus, the frequency of nonclonal cells by G6PD analysis correlated closely with that of the Ph1-negative cells. The data indicate that intensive chemotherapy can restore nonclonal and presumably non-neoplastic hematopoiesis in CML.
13
Philip J. Fialkow, A. M. Denman, Robert J. Jacobson et al. · Journal of Clinical Investigation · 1978 · 324 citations · Full text
I Cunningham, T Gee, Monroe D. Dowling et al. · Blood · 1979 · 191 citations · Full text
Medicine, Hematology, Oncology +9